Clinical Trial

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

Study acronym: LUSPLUS
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-12-20; most recent amendment 2025-09-29.
Status change: Recruiting → Active, Not Recruiting 2025-09-29
Trial Details
NCT Number NCT05181592
Lead Sponsor GWT-TUD GmbH
Collaborators: Celgene
Conditions Myelodysplastic Syndromes
Enrollment 70 participants
Start Date 2021-10-27
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-09-30